NeutroSpec Promos Tout Broad, Unsupported Indications, FDA Chides
This article was originally published in The Pink Sheet Daily
The withdrawn imaging agent is cited for violations made during the 2005 American Pharmaceutical Association annual meeting.
You may also be interested in...
FDA "reconsidered" the risk/benefit balance for Mallinckrodt/Palatin Technologies' appendicitis imaging agent, which has been associated with cardiopulmonary events.
Raising US corporate taxes would reduce corporate investment in the US and particularly impact jobs, Johnson & Johnson chief financial officer Joseph Wolk cautioned during the company's first quarter sales and earnings call on 20 April.
The company recorded $100m in revenues from the vaccine in the first quarter, before administration was paused in the US and Europe to review a rare risk of blood clots.